117 related articles for article (PubMed ID: 7865238)
1. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma.
Rasmuson T; Björk GR
Acta Oncol; 1995; 34(1):61-7. PubMed ID: 7865238
[TBL] [Abstract][Full Text] [Related]
2. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1985; 8(1-2):287-90. PubMed ID: 4064048
[TBL] [Abstract][Full Text] [Related]
3. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387
[TBL] [Abstract][Full Text] [Related]
4. Comparison of urinary neopterin and pseudouridine in patients with malignant proliferative diseases.
Motyl T; Traczyk Z; Holska W; Daniewska-Michalska D; Cieśluk S; Kukulska W; Kałuzny Z; Podgurniak M
Eur J Clin Chem Clin Biochem; 1993 Apr; 31(4):205-9. PubMed ID: 8318566
[TBL] [Abstract][Full Text] [Related]
5. Excretion of pseudouridine as an independent prognostic factor in renal cell carcinoma.
Rasmuson T; Björk GR; Hietala SO; Stenling R; Ljungberg B
Acta Oncol; 1991; 30(1):11-5. PubMed ID: 2009178
[TBL] [Abstract][Full Text] [Related]
6. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
7. Urinary neopterin in malignant lymphoma.
Piccinini L; Zironi S; Federico M; Pini LA; Luppi G
Int J Biol Markers; 1991; 6(4):231-6. PubMed ID: 1795130
[TBL] [Abstract][Full Text] [Related]
8. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma.
Itoh K; Konno T; Sasaki T; Ishiwata S; Ishida N; Misugaki M
Clin Chim Acta; 1992 Mar; 206(3):181-9. PubMed ID: 1606704
[TBL] [Abstract][Full Text] [Related]
9. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
[TBL] [Abstract][Full Text] [Related]
10. The influence of histologic type on survival in early extranodal non-Hodgkin's lymphoma in head and neck.
Aozasa K; Nara H; Ikeda H; Masaki N; Miyata Y; Matsuzuka F; Shigematsu Y
Oncology; 1984; 41(3):164-9. PubMed ID: 6728399
[TBL] [Abstract][Full Text] [Related]
11. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.
Gotti M; Nicola M; Lucioni M; Fiaccadori V; Ferretti V; Sciarra R; Costanza M; Bono E; Molo S; Maffi A; Croci GA; Varettoni M; Frigeni M; Pascutto C; Arcaini L; Bonfichi M; Paulli M; Cazzola M
Hematol Oncol; 2017 Sep; 35(3):296-302. PubMed ID: 27060262
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification.
Leonard RC; Cuzick J; MacLennan IC; Vanhegan RI; Mackie PH; McCormick CV
Br J Cancer; 1983 Jan; 47(1):91-102. PubMed ID: 6821635
[TBL] [Abstract][Full Text] [Related]
13. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
14. Comparison of S-phase fraction, working formulation, and Kiel classification in non-Hodgkin's lymphoma.
Joensuu H; Klemi PJ; Söderström KO; Jalkanen S
Cancer; 1991 Oct; 68(7):1564-71. PubMed ID: 1893358
[TBL] [Abstract][Full Text] [Related]
15. Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
Heinz R; Hanak H; Stacher A
Klin Wochenschr; 1985 Jul; 63(14):619-26. PubMed ID: 3839867
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factors of invasive non-Hodgkin's lymphoma].
Yu H; Hong XN; Li J; Peng LP; Ye L
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):461-3. PubMed ID: 17974284
[TBL] [Abstract][Full Text] [Related]
18. Blood plasma pseudouridine in patients with malignant proliferative diseases.
Motyl T; Traczyk Z; Cieśluk S; Daniewska-Michalska D; Kukulska W; Kałuzny Z; Podgurniak M; Orzechowski A; Debski B
Eur J Clin Chem Clin Biochem; 1993 Nov; 31(11):765-71. PubMed ID: 8305621
[TBL] [Abstract][Full Text] [Related]
19. [Clinical relevance of the Kiel classification of non-Hodgkin's lymphomas (author's transl)].
Stacher A; Heinz R; Waldner R; Böhnel J
Wien Klin Wochenschr; 1980 Aug; 92(15):520-5. PubMed ID: 7001765
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.
Simon R; Durrleman S; Hoppe RT; Bonadonna G; Bloomfield CD; Rudders RA; Cheson BD; Berard CW
Med Pediatr Oncol; 1990; 18(2):89-96. PubMed ID: 2406556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
